Table 4.
GEE models for the impact of clinical factors on the final BCVA after treatment.
| All subjects | Responder group | Non-responder group | ||||
|---|---|---|---|---|---|---|
| B (S.E.) | P value | B (S.E.) | P value | B (S.E.) | P value | |
| Age (years) | 0.016 (0.005) | 0.001* | 0.002 (0.004) | 0.555 | 0.008 (0.005) | 0.070 |
| HbA1c (%) | 0.057 (0.033) | 0.085 | 0.060 (0.024) | 0.013* | −0.019 (0.027) | 0.481 |
| Baseline BCVA (LogMAR) | 0.478 (0.228) | 0.036* | 0.343 (0.301) | 0.254 | 0.745 (0.233) | 0.001* |
| Baseline CST (μm) | 0.002 (0.001) | 0.062 | 0.002 (0.001) | 0.019* | 0.002 (0.001) | 0.002* |
| PDR | −0.005 (0.098) | 0.962 | −0.083 (0.067) | 0.217 | 0.144 (0.061) | 0.019* |
| No of IVI | 0.070 (0.033) | 0.035* | 0.061 (0.032) | 0.055 | 0.016 (0.020) | 0.401 |
B (S.E.): regression coefficient (standard error), BCVA: best corrected visual acuity, CST: central subfield thickness, HbA1C: glycosylated hemoglobin, IVI: intravitreal injection, PDR: Proliferative diabetic retinopathy, *P < 0.05.